Venetoclax resistance: mechanistic insights and future strategies

Abstract

Acute myeloid leukemia (AML) is historically associated with poor prognosis, especially in older AML patients unfit for intensive chemotherapy. The development of Venetoclax, a potent oral BH3 (BCL-2 homology domain 3) mimetic, has transformed the AML treatment. However, the short duration of response and development of resistance remain major concerns. Understanding mechanisms of resistance is pivotal to devising new strategies and designing rational drug combination regimens. In this review, we will provide a comprehensive summary of the known mechanisms of resistance to Venetoclax and discuss Venetoclax-based combination therapies. Key contributing factors to Venetoclax resistance include dependencies on alternative anti-apoptotic BCL-2 family proteins and selection of the activating kinase mutations. Mutational landscape governing response to Venetoclax and strategic approaches developed considering current knowledge of mechanisms of resistance will be addressed.

Keywords

Venetoclax / acute myeloid leukemia / hypomethylating agents / Azacitidine / Decitabine / resistance / BCL2 protein / human

References

[1] Howlader N NA,Miller D. SEER Cancer Statistics Review, 1975-2017. National Cancer Institute. Available from: https://seer.cancer.gov/csr/1975_2017/ [Last accessed on 6 Apr 2022].

[2] Döhner H,Grimwade D.Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.Blood2017;129:424-47 PMCID:PMC5291965

[3] Short NJ,Kadia TM.Advances in the treatment of acute myeloid leukemia: new drugs and new challenges.Cancer Discov2020;10:506-25

[4] Konopleva M,Potluri J.Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia.Cancer Discov2016;6:1106-17 PMCID:PMC5436271

[5] Food and Drug Administration. FDA grants regular approval to venetoclax in combination for untreated acute myeloid leukemia. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-venetoclax-combination-untreated-acute-myeloid-leukemia [Last accessed on 6 Apr 2022]

[6] DiNardo CD,Benton C.Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.Am J Hematol2018;93:401-7

[7] Maiti A,Cortes JE.Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens.Haematologica2021;106:894-8 PMCID:PMC7927994

[8] Souers AJ,Boghaert ER.ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.Nat Med2013;19:202-8

[9] Roberts AW.Therapeutic development and current uses of BCL-2 inhibition.Hematology Am Soc Hematol Educ Program2020;2020:1-9 PMCID:PMC7727569

[10] Bose P,Konopleva M.Pathways and mechanisms of venetoclax resistance.Leuk Lymphoma2017;58:1-17 PMCID:PMC5478500

[11] Kale J,Andrews DW.BCL-2 family proteins: changing partners in the dance towards death.Cell Death Differ2018;25:65-80 PMCID:PMC5729540

[12] Kapoor I,Hill BT,Almasan A.Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance.Cell Death Dis2020;11:941 PMCID:PMC7608616

[13] Pan R,Benito JM.Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.Cancer Discov2014;4:362-75 PMCID:PMC3975047

[14] Zhu R,Nguyen B.FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation.Signal Transduct Target Ther2021;6:186 PMCID:PMC8141515

[15] Campos L,Sabido O.High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 1993;81(11):3091-3096. Available from: https://www.ncbi.nlm.nih.gov/pubmed/7684624 [Last accessed on 6 Apr 2022].

[16] Delia D,Soligo D.bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood. 1992;79(5):1291-1298. Available from: https://www.ncbi.nlm.nih.gov/pubmed/1536952 [Last accessed on 6 Apr 2022].

[17] Lauria F,Rondelli D.High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate.Leukemia1997;11:2075-8

[18] Lagadinou ED,Callahan K.BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.Cell Stem Cell2013;12:329-41 PMCID:PMC3595363

[19] Leverson JD,Mitten MJ.Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.Sci Transl Med2015;7:279ra40

[20] Bensi L,Vecchi A.Bcl-2 oncoprotein expression in acute myeloid leukemia. Haematologica. 1995;80(2):98-102. Available from: https://www.ncbi.nlm.nih.gov/pubmed/7628759 [Last accessed on 6 Apr 2022].

[21] Ishizawa J,McQueen T.Mitochondrial profiling of acute myeloid leukemia in the assessment of response to apoptosis modulating drugs.PLoS One2015;10:e0138377 PMCID:PMC4573975

[22] Niu X,Wang Y.Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199.Leukemia2014;28:1557-60 PMCID:PMC4090260

[23] Salah HT,Konopleva M.Potential biomarkers for treatment response to the bcl-2 inhibitor venetoclax: state of the art and future directions.Cancers (Basel)2021;13:2974 PMCID:PMC8231978

[24] Chyla B,Doyle K.Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia.Am J Hematol2018:E202-5 PMCID:PMC6120451

[25] Crews LA,Delos Santos NP.RNA Splicing modulation selectively impairs leukemia stem cell maintenance in secondary human AML.Cell Stem Cell2016;19:599-612 PMCID:PMC5097015

[26] Chan SM,Corces-Zimmerman MR.Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.Nat Med2015;21:178-84 PMCID:PMC4406275

[27] Stuani L,Saland E.Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia.J Exp Med2021;218:e20200924 PMCID:PMC7995203

[28] Pollyea DA,Jones CL.Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia.Nat Med2018;24:1859-66 PMCID:PMC7001730

[29] Lachowiez CA,Loghavi S.Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies.JCO2020;38:7500-7500

[30] Cathelin S,Subedi A.Combination of enasidenib and venetoclax shows superior anti-leukemic activity against IDH2 mutated AML in patient-derived xenograft models.Blood2018;132:562-562

[31] Daver N,Pollyea DA,Vyas P.New directions for emerging therapies in acute myeloid leukemia: the next chapter.Blood Cancer J2020;10:107 PMCID:PMC7599225

[32] DiNardo CD,Quaglieri A.Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.Blood2020;135:791-803 PMCID:PMC7068032

[33] Tiong IS,Ivey A.Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.Br J Haematol2021;192:1026-30 PMCID:PMC8048658

[34] Rahmani NE,Sahu S.ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine.Blood Cancer J2021;11:157 PMCID:PMC8455571

[35] Lin KH,Xie A.Targeting MCL-1/BCL-XL Forestalls the acquisition of resistance to ABT-199 in acute myeloid leukemia.Sci Rep2016;6:27696 PMCID:PMC4901329

[36] Bisaillon R,Thiollier C.Genetic characterization of ABT-199 sensitivity in human AML.Leukemia2020;34:63-74

[37] Zhang H,Köhnke T.Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia.Nat Cancer2020;1:826-39 PMCID:PMC7591155

[38] Ma J,Qiao X.Inhibition of Bcl-2 Synergistically enhances the antileukemic activity of midostaurin and gilteritinib in preclinical models of FLT3-mutated acute myeloid leukemia.Clin Cancer Res2019;25:6815-26 PMCID:PMC6858954

[39] Niu X,Ma J.Binding of released bim to Mcl-1 is a mechanism of intrinsic resistance to ABT-199 which can be overcome by combination with daunorubicin or cytarabine in AML cells.Clin Cancer Res2016;22:4440-51 PMCID:PMC5010519

[40] Zhang Q,Han L.Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.Signal Transduct Target Ther2022;7:51

[41] Tse C,Adickes J.ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.Cancer Res2008;68:3421-8

[42] Schoenwaelder SM,Gardiner EE.Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets.Blood2011;118:1663-74

[43] Moujalled DM,Ghiurau C.Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia.Leukemia2019;33:905-17 PMCID:PMC6484700

[44] Ramsey HE,Lee T.A Novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia.Cancer Discov2018;8:1566-81 PMCID:PMC6279595

[45] Wang H,Wei H.Targeting MCL-1 in cancer: current status and perspectives.J Hematol Oncol2021;14:67 PMCID:PMC8061042

[46] Roberts AW,Huang DCS.BCL2 and MCL1 inhibitors for hematologic malignancies.Blood2021;138:1120-36

[47] Wei AH,Spencer A.Targeting MCL-1 in hematologic malignancies: Rationale and progress.Blood Rev2020;44:100672 PMCID:PMC7442684

[48] Kasper S,Heidel F.Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies.Blood Cancer J2012;2:e60 PMCID:PMC3317524

[49] Singh Mali R,DeFilippis RA.Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models.Haematologica2021;106:1034-46 PMCID:PMC8017817

[50] Yoshimoto G,Jabbarzadeh-Tabrizi S.FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation.Blood2009;114:5034-43 PMCID:PMC2788977

[51] Dumon S,Debierre-Grockiego F.IL-3 dependent regulation of Bcl-xL gene expression by STAT5 in a bone marrow derived cell line.Oncogene1999;18:4191-9

[52] Young AI,Gallego-Ortega D,Oakes SR.Myeloid cell leukemia 1 (MCL-1), an unexpected modulator of protein kinase signaling during invasion.Cell Adh Migr2018;12:513-23 PMCID:PMC6363037

[53] Pan R,Mu H.Synthetic lethality of combined Bcl-2 inhibition and p53 activation in AML: mechanisms and superior antileukemic efficacy.Cancer Cell2017;32:748-760.e6 PMCID:PMC5730338

[54] Moujalled DM,Pomilio G.Acquired mutations in BAX confer resistance to BH3 mimetics in acute myeloid leukemia.Blood2020;136:7-8

[55] Nechiporuk T,Nikolova O.The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells.Cancer Discov2019;9:910-25 PMCID:PMC6606338

[56] Chen X,Zhou H.Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment.Cancer Discov2019;9:890-909 PMCID:PMC6606342

[57] Aubrey BJ,Janic A,Strasser A.How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?.Cell Death Differ2018;25:104-13 PMCID:PMC5729529

[58] Fischer M.Census and evaluation of p53 target genes.Oncogene2017;36:3943-56 PMCID:PMC5511239

[59] Carter BZ,Tao W.Co-Targeting MCL-1 and BCL-2 is highly synergistic in BH3 mimetic- and venetoclax/hypomethylating agent-resistant and TP53 mutated AML.Blood2020;136:7-7

[60] Thijssen R,Moujalled D.Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.Blood2021;137:2721-35 PMCID:PMC8138548

[61] Sharon D,Mirali S.Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response.Sci Transl Med2019;11:eaax2863

[62] Bennett JM,Daniel MT.Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group.Br J Haematol1976;33:451-8

[63] Kuusanmäki H,Pölönen P.Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia.Haematologica2020;105:708-20 PMCID:PMC7049363

[64] Pei S,Gustafson A.Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia.Cancer Discov2020;10:536-51 PMCID:PMC7124979

[65] Issa GC,DiNardo CD,Kantarjian HM.Therapeutic implications of menin inhibition in acute leukemias.Leukemia2021;35:2482-95

[66] DiNardo CD,Pullarkat V.Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.Blood2019;133:7-17

[67] Jozal W Moore,John L Reagan.Azacitidine and venetoclax in AML.N Engl J Med2020;383:2087-9

[68] Dinardo CD,Rausch CR.10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.The Lancet Haematology2020;7:e724-36

[69] Wei AH,Hou JZ.Venetoclax Combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study.J Clin Oncol2019;37:1277-84 PMCID:PMC6524989

[70] Dombret H,Butrym A.International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.Blood2015;126:291-9 PMCID:PMC4504945

[71] Thépot S,Seegers V.Groupe Francophone des Myélodysplasies (GFM)Acute Leukemia French Association (ALFA); Groupe Ouest-Est des Leucémies Aiguës; Maladies du Sang (GOELAMS)Azacitidine in untreated acute myeloid leukemia: a report on 149 patients.Am J Hematol2014;89:410-6

[72] Kantarjian HM,Dmoszynska A.Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.J Clin Oncol2012;30:2670-7 PMCID:PMC4874148

[73] He PF,Yao DM.Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis.Oncotarget2017;8:41498-507 PMCID:PMC5522197

[74] Bogenberger JM,Pierceall WE.BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.Leukemia2014;28:1657-65 PMCID:PMC4131248

[75] Bogenberger JM,Hansen N.Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies.Leuk Lymphoma2015;56:226-9 PMCID:PMC4331188

[76] Tsao T,Kornblau S.Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells.Ann Hematol2012;91:1861-70 PMCID:PMC3750747

[77] DiNardo CD,Pullarkat V.Azacitidine and venetoclax in previously untreated acute myeloid leukemia.N Engl J Med2020;383:617-29

[78] Samra B,Isidori A,DiNardo C.Venetoclax-based combinations in acute myeloid leukemia: current evidence and future directions.Front Oncol2020;10:562558 PMCID:PMC7675064

[79] Dennis M,Russell NH.An evaluation of 17 years of low dose cytarabine as therapy for AML patients not fit for intensive treatment, including patients with adverse cytogenetics, shows improving survival, potential underutilisation and highlights the need for new therapy.Blood130(Supplement 1):3874-3874

[80] Wei AH,Ivanov V.Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.Blood2020;135:2137-45 PMCID:PMC7290090

[81] DiNardo CD,Takahashi K.Venetoclax combined with flag-ida induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia.J Clin Oncol2021;39:2768-78

[82] Chua CC,Reynolds J.Chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT): a phase ib dose-escalation study of venetoclax combined with modified intensive chemotherapy.J Clin Oncol2020;38:3506-17

[83] Kadia TM,Pemmaraju N.Phase II study of venetoclax added to cladribine + low dose AraC (LDAC) alternating with 5-azacytidine demonstrates high rates of minimal residual disease (MRD) negative complete remissions (CR) and excellent tolerability in older patients with newly diagnosed acute myeloid leukemia (AML).Blood2020;136:17-9

[84] Stahl M,Derkach A.Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML.Blood Adv2021;5:1552-64 PMCID:PMC7948282

[85] Wang YW,Lin CC.Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax.Ann Hematol2020;99:501-11

[86] Carter BZ,Mak PY.Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML.Blood2021;138:1637-41 PMCID:PMC8554651

[87] Lachowiez CA,Furudate K.Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax.Blood Adv2021;5:2173-83 PMCID:PMC8095152

[88] Kim K,Loghavi S.Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax.Cancer2021;127:3772-81

[89] Aldoss I,Pillai R.Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia.Br J Haematol2019;187:e45-8 PMCID:PMC6786919

[90] Schoch C,Kohlmann A,Schnittger S.Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile.Genes Chromosomes Cancer2005;43:227-38

[91] Perl AE,Pratz KW.Venetoclax in combination with gilteritinib in patients with relapsed/refractory acute myeloid leukemia: a phase 1b study.Blood2019;134:3910-3910

[92] Yilmaz M,Muftuoglu M.Quizartinib with decitabine and venetoclax (triplet) is highly active in patients with FLT3-ITD mutated acute myeloid leukemia (AML).JCO2021;39:e19019-e19019

[93] Yue X,He J.Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies.Cancer Cell Int2020;20:524 PMCID:PMC7597043

[94] Bolomsky A,Köse MC.MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents.J Hematol Oncol2020;13:173 PMCID:PMC7731749

[95] Rasmussen ML,Neininger AC.MCL-1 Inhibition by selective BH3 mimetics disrupts mitochondrial dynamics causing loss of viability and functionality of human cardiomyocytes.iScience2020;23:101015 PMCID:PMC7155208

[96] Bogenberger J,Hansen N.Combined venetoclax and alvocidib in acute myeloid leukemia.Oncotarget2017;8:107206-22 PMCID:PMC5739808

[97] Knorr KL,Meng XW.MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors.Cell Death Differ2015;22:2133-42 PMCID:PMC4816118

[98] Han L,Dail M.Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models.Haematologica2020;105:697-707 PMCID:PMC7049339

[99] Short N BP. Preliminary Results Of A Phase I/II Study of azacitidine, venetoclax and pevonedistat in patients with secondary acute myeloid leukemia who are unfit for intensive chemotherapy. HemaSphere. 2020;4:232. Available from: https://library.ehaweb.org/eha/2020/eha25th/294475/nicholas.short.preliminary.results.of.a.phase.i.ii.study.of.azacitidine.html [Last accessed on 6 Apr 2022]

[100] Daver N,Yee KW.Preliminary results from a phase ib study evaluating BCL-2 inhibitor venetoclax in combination with MEK inhibitor cobimetinib or MDM2 inhibitor idasanutlin in patients with relapsed or refractory (R/R) AML.Blood2017;130:813-813

[101] Khurana A.MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388).Onco Targets Ther2019;12:2903-10 PMCID:PMC6563714

[102] Lu J,Zhao Y.Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma.Oncotarget2016;7:82757-69 PMCID:PMC5347730

[103] Zhang Q,Wiman KG.APR-246 reactivates mutant p53 by targeting cysteines 124 and 277.Cell Death Dis2018;9:439 PMCID:PMC5906465

[104] Chao MP,Feng DD.Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies.Front Oncol2019;9:1380 PMCID:PMC6990910

[105] Majeti R,Alizadeh AA.CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.Cell2009;138:286-99 PMCID:PMC2726837

[106] Sallman DA,Asch AS.The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results.JCO2019;37:7009-7009

[107] Donio MJ,Darwech I.Pre-clinical combination of AO-176, a highly differentiated clinical stage CD47 antibody, with either azacitidine or venetoclax significantly enhances DAMP induction and phagocytosis of acute myeloid leukemia.Blood2020;136:9-10

[108] Krause DS.Evading eviction: leukemic stem cell squatters.Blood2021;138:1007-8

[109] Konopleva M,Zeng Z.Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches.Drug Resist Updat2009;12:103-13 PMCID:PMC3640296

[110] Yu X,Streule K.CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues.Blood2021;138:1067-80

[111] Zhou W,Liu M,Wang G.Targeting CXCL12/CXCR4 axis in tumor immunotherapy.Curr Med Chem2019;26:3026-41 PMCID:PMC5949083